Core Insights - Elutia Inc. has entered into an agreement with Vizient to provide access to its EluPro Antibiotic Eluting BioEnvelope to Southern Strategic Sourcing Partners (S3P), which includes 993 acute care facilities [1][3] - EluPro is the first antibiotic-eluting biologic envelope approved by the FDA for use with cardiac implantable electronic devices and neurostimulators, addressing post-surgical challenges such as infection and skin erosion [2] - The partnership with S3P is a significant milestone for Elutia, marking its second major group purchasing organization (GPO) partnership ahead of EluPro's full commercial launch [3] Company Overview - Elutia develops drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [4] - The company is focused on addressing the needs of a growing population requiring implantable technologies [4]
Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners